Comparative Pharmacology
Head-to-head clinical analysis: CETIRIZINE versus PROMETH PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CETIRIZINE versus PROMETH PLAIN.
Cetirizine vs PROMETH PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine is a selective second-generation H1-receptor antagonist that inhibits histamine release from mast cells and basophils, thereby reducing allergic symptoms.
Antagonist at histamine H1 receptors; also exhibits anticholinergic, antiemetic, and sedative effects.
10 mg orally once daily; 5 mg orally once daily for mild symptoms
12.5-25 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 100 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 8.3 hours in healthy adults; extended to 20 hours in elderly and patients with renal impairment
Clinical Note
moderateCetirizine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Cetirizine is combined with Fluticasone propionate."
Clinical Note
moderateLevocetirizine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Levocetirizine."
Clinical Note
moderateLevocetirizine + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Levocetirizine."
Clinical Note
moderateLevocetirizine + Cyclosporine
Terminal elimination half-life is 10-14 hours in adults; may be prolonged in elderly or hepatic impairment.
Primarily renal (60% unchanged in urine); minor biliary/fecal (10%)
Primarily renal (approximately 70%) as metabolites and unchanged drug; biliary/fecal excretion accounts for ~20%.
Category A/B
Category C
Antihistamine
Antihistamine
"The metabolism of Cyclosporine can be decreased when combined with Levocetirizine."